What is the forecast for Ascendis Pharma's stock?
Ascendis Pharma A/S (ASND) maintains a strong consensus Buy rating among biopharmaceutical analysts, with average 12-month price targets clustering around $309.18 per share. Valuation frameworks incorporate commercial revenue scaling for its flagship endocrinology treatments, global market expansion of its TransCon drug delivery technology platform, and clinical pipeline advancements addressing rare endocrine and oncology diseases.
Related FAQs
Ascendis Health underwent extensive corporate restructuring, debt-reduction initiatives, and strategic asset divestments to address historical financial leverage and streamline operations.
Equity research analysts tracking Ascendis Pharma (ticker ASND) frequently assign consensus ratings leaning toward a buy or strong buy, driven by the successful commercial expansion of its innovative endocrinology therapeutics and growing global reve...
Ashtead Group (operating primarily through its Sunbelt Rentals subsidiary) commands a massive equipment rental fleet valued at over $15 billion across its operations in the United States, alongside substantial fleet allocations in Canada and the Unit...
Ascendis Pharma is a biopharmaceutical enterprise dedicated to applying its proprietary TransCon drug-development technology platform to create innovative, long-acting therapeutic treatments for rare endocrine diseases and oncology.
Ascendis Pharma A/S, trading under the ticker ASND on the Nasdaq stock exchange, operates as a biopharmaceutical enterprise utilizing its proprietary TransCon technology platform to develop best-in-class therapeutics for unmet medical needs, includin...
Ascendis Pharma is widely recognized as an innovative, highly respected global biopharmaceutical enterprise dedicated to developing advanced therapies using its proprietary TransCon technology platform.
Ascendis Pharma A/S, traded under the ticker symbol ASND, belongs to the healthcare sector and operates specifically within the biotechnology and biopharmaceutical industry.
Ascendis Pharma demonstrates exceptional growth prospects driven by the successful commercial scaling of its proprietary TransCon technology platform and flagship commercial products like YORVIPATH.
Ascendis Pharma operates through a strategically distributed model with two primary operational hubs.
Ascendis Pharma utilizes its proprietary TransCon technology platform to develop innovative long-acting prodrug therapies designed to address unmet medical needs in endocrinology and rare diseases.
Determining whether Ascendis Pharma stock represents an attractive purchase involves analyzing its proprietary TransCon technology platform, expanding commercial product portfolio, and strengthening bottom-line financial performance.
Ascendis Pharma operates as a fully public corporate entity, listed and traded on major global stock exchanges including The Nasdaq Global Select Market under its primary ticker designation.
Corporate entities operating under the name Ascendis—specifically major biopharmaceutical operations—have achieved profitability milestones driven by strong commercial product sales, growing international market penetration, and disciplined cost cont...
Ascendis Pharma is a biopharmaceutical company utilizing its proprietary TransCon technology platform to develop a robust pipeline of long-acting prodrug therapies that address unmet medical needs in rare endocrine diseases and oncology.
Ascendis Pharma A/S is a global biopharmaceutical company headquartered in Hellerup, Denmark, which is a northern suburb of Copenhagen.
Bausch + Lomb Corporation (NYSE: BLCO) stock has experienced moderate downward volatility and relative pressure over past annual cycles, trading down roughly 21 percent over a trailing one-year period.
Ascendis Pharma develops and manufactures a specialized portfolio of therapeutic products utilizing its proprietary TransCon technology platform, which is designed to create long-acting prodrugs that release active parent medications steadily over ti...
Ascendis Pharma maintains deep corporate roots and operational headquarters in Copenhagen, Denmark, establishing its primary European identity while operating globally.
Employee reviews and corporate workplace evaluations for Ascendis Pharma consistently highlight a collaborative scientific environment, competitive compensation packages, and robust professional growth opportunities within the biotechnology sector.
ASE Technology Holding Co., Ltd. commands a market capitalization of approximately $83.20 billion to $86.68 billion USD, positioning it as a dominant global leader in semiconductor packaging and testing services.
Ascendis Pharma has successfully transitioned into a profitable commercial-stage enterprise, generating robust product revenues from its flagship commercial therapies alongside positive operating profits and growing cash flows.
Ascendis Pharma is a commercial-stage biopharmaceutical company globally known for applying its innovative proprietary TransCon technology platform to develop best-in-class therapeutics that address significant unmet medical needs in endocrinology an...
ASSA ABLOY AB, the global leader in access solutions and physical security products, employs approximately 55,000 to 64,000 personnel worldwide across its various specialized divisions and operating subsidiaries.